Rodrik-Outmezguine, Vanessa S.
Okaniwa, Masanori
Yao, Zhan
Novotny, Chris J.
McWhirter, Claire
Banaji, Arpitha
Won, Helen
Wong, Wai
Berger, Mike
de Stanchina, Elisa
Barratt, Derek G.
Cosulich, Sabina
Klinowska, Teresa
Rosen, Neal
Shokat, Kevan M.
Article History
Received: 29 October 2015
Accepted: 31 March 2016
First Online: 18 May 2016
Competing interests
: K.M.S. is an inventor on patents related to MLN0128 held by the University of California San Francisco (UCSF), and sublicensed to Takeda Pharmaceuticals. N.R. and K.M.S. are consultants and M.O. is an employee at Takeda Pharmaceuticals Company Limited, which is conducting MLN0128 clinical trials. C.M., D.G.B., S.C. and T.K. are employees at AstraZeneca, which is conducting AZD2014 (mTOR kinase inhibitor) trials. K.M.S. and M.O. are inventors on a patent application related to RapaLink held by UCSF and licensed to Kura Oncology. K.M.S. is a shareholder in Kura Oncology, K.M.S. and N.R. are consultants to Kura Oncology.